Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Weisberg

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|May 17, 2021
3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistanceKinan Alhallak, Pilar de la Puente, Amanda Jeske, et al.
Cell Chemical Biology|October 24, 2017
Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7Ilaria Lamberto, Xiaoxi Liu, Hyuk-Soo Seo, et al.
European Journal of Medicinal Chemistry|October 30, 2025
Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domainMarina C Primi, Maurício T Tavares, John M Hatcher, et al.
Leukemia|February 24, 2015
Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cellsHaymanti Bhanot, Mamatha M Reddy, Atsushi Nonami, et al.
Oncotarget|September 9, 2017
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinaseEllen L Weisberg, Alexandre Puissant, Richard Stone, et al.
Leukemia|July 4, 2015
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AMLH Wu, C Hu, A Wang, et al.
Haematologica|April 18, 2020
Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemiaAoli Wang, Chen Hu, Cheng Chen, et al.
Bioorganic & Medicinal Chemistry|January 1, 2017
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitorsLi Tan, Deepak Gurbani, Ellen L Weisberg, et al.
ACS Chemical Biology|August 1, 2013
Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitorHyung-Gu Kim, Li Tan, Ellen L Weisberg, et al.
Cancers|December 30, 2020
Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)Moshe Lapidot, Abigail E Case, Dalia Larios, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|May 17, 2021
3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistanceKinan Alhallak, Pilar de la Puente, Amanda Jeske, et al.
Cell Chemical Biology|October 24, 2017
Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7Ilaria Lamberto, Xiaoxi Liu, Hyuk-Soo Seo, et al.
European Journal of Medicinal Chemistry|October 30, 2025
Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domainMarina C Primi, Maurício T Tavares, John M Hatcher, et al.
Leukemia|February 24, 2015
Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cellsHaymanti Bhanot, Mamatha M Reddy, Atsushi Nonami, et al.
Oncotarget|September 9, 2017
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinaseEllen L Weisberg, Alexandre Puissant, Richard Stone, et al.
Leukemia|July 4, 2015
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AMLH Wu, C Hu, A Wang, et al.
Haematologica|April 18, 2020
Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemiaAoli Wang, Chen Hu, Cheng Chen, et al.
Bioorganic & Medicinal Chemistry|January 1, 2017
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitorsLi Tan, Deepak Gurbani, Ellen L Weisberg, et al.
ACS Chemical Biology|August 1, 2013
Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitorHyung-Gu Kim, Li Tan, Ellen L Weisberg, et al.
Cancers|December 30, 2020
Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)Moshe Lapidot, Abigail E Case, Dalia Larios, et al.
Pageof 8